No abstract available.
Breast* ; DNA* ; P-Glycoprotein*

Extranodal NK/T-cell lymphoma (ENKL) is a rare subtype of NHL (Non-Hodgkin lymphoma]. It occurs mostly in the nasal and paranal areas. Most of the cases are presented stage I/II. International prognostic index (IPI) can predict the outcome. However, better prognostic model is available such as NKIPI. Because of high expression of p-glycoprotein, ENKL is refractory to chemotherapy. Early stage disease can be bestly treated with concurrent chemoradiation. For advanced stage disease, new clinical trials are now being conducted.
Lymphoma ; P-Glycoprotein

No abstract available.
P-Glycoprotein* ; Stomach Neoplasms*

No abstract available.
Leukemia, Monocytic, Acute* ; P-Glycoprotein*

OBJECTIVE: We determined the influence of 3-OMD in the protein binding of levodopa to estimate the effect of 3-OMD on the penetration of levodopa into brain. METHOD: P-glycoprotein in the brain may serve to limit drug penetration into the brain. Because it is not available as an experimental substance, but has similar binding properties with alpha 1 acid glycoprotein(AGP), we used AGP in this study. Additionally, we used blood plasma to see the affinity of plasma binding of levodopa. The final concentration of chemicals used in this study were 125, 250, 500, 1000, 2000, 4000 microgram/l for levodopa and 0, 1250, 5000, 10,000 microgram/l for 3-OMD, 1 mg/l for AGP. The free fraction of levodopa in blood plasma and AGP were separated by ultrafiltration method and determined by beta-counter, respectively. RESULTS: We found that levodopa did not bind with AGP, but only 22-24% from 125 microgram/l to 4000 microgram/l of it bound with blood plasma. The addition of 3-OMD to the blood plasma did not significantly change the binding of levodopa. CONCLUSIONS: We can conclude that 3-OMD does not influence the penetration of levodopa into brain. These small amount of the binding does not expect to influence to other drugs on the binding with plasma.
Brain ; Drug Interactions ; Levodopa* ; P-Glycoprotein ; Plasma* ; Protein Binding ; Ultrafiltration

No abstract available.
Carcinoma, Transitional Cell* ; Humans* ; P-Glycoprotein* ; Urinary Bladder*

Oseltamivir is a substrate of P-glycoprotein, an efflux drug transporter encoded by ABCB1. The objective of this study was to assess the role of ABCB1 (c.1236C>T, c.2677G>T/A, and c.3435C>T) polymorphisms in the pharmacokinetics of oseltamivir and its active metabolite, oseltamivir carboxylate in humans. Nineteen healthy male subjects were enrolled, and their ABCB1 polymorphisms were evaluated. After the oral administration of 75 mg oseltamivir, the plasma concentrations of oseltamivir and oseltamivir carboxylate were measured. Pharmacokinetic analysis was carried out. Systemic exposure to oseltamivir and oseltamivir carboxylate was higher in the mutant group than in the wild-type and heterozygous groups. We suggest that ABCB1 polymorphisms affect the pharmacokinetics of oseltamivir in humans. Further studies in a large population are necessary to validate the results of this preliminary study (Clinical Trial Registration Information [CRIS] registry: http://cris.nih.go.kr, No. KCT0001903).
Administration, Oral ; Humans* ; Male ; Oseltamivir* ; P-Glycoprotein ; Pharmacokinetics* ; Plasma

OBJECTIVES: The purpose of this study was to evaluate expression of cyclooxygenase-2 (COX-2) and P-glycoprotein (P-gp) in ovarian epithelial carcinomas, to find out the correlations between their expression and clinicopathological parameters, and to evaluate the response to treatment and clinical outcome according to their expression. METHODS: Immunohistochemical studies of COX-2 and P-gp were carried out in 64 cases that were treated with ovarian epithelial carcinomas at Department of Obstetrics and Gynecology, Korea University Hospital, Korea University from 1996 to 2005. RESULTS: COX-2 over-expression was detected in 20 (31.2%) cases and was significantly higher in non-responder than responder to chemotherapy (56.2% versus 22.9%, respectively; P=0.012). The patients of COX-2 overexpression showed shorter overall survival (P<0.001). Over-expression of P-gp was detected in 15 (23.4%) cases was significantly higher in non-responder than responder to chemotherapy (56.2% versus 12.5%, respectively; P<0.001). The patients of P-gp overexpression showed shorter overall survival (P= 0.042). CONCLUSION: COX-2 and P-gp overexpression could provide additional information to identify ovarian carcinoma patients with poor chance of response to chemotherapy.
Cyclooxygenase 2* ; Drug Therapy ; Gynecology ; Humans ; Korea ; Obstetrics ; P-Glycoprotein* ; Prognosis

BACKGROUND: Some researchers have tried to use Tc-99m MIBI (2-methoxyisobutyl isonitril) scintigraphy to evaluate breast-cancer patients. Early reports revealed that Tc-99m MIBI breast scintigraphy was useful in distinguishing malignancies from benign masses in patients for whom mammographic evaluations were difficult. Further studies suggested that functional imaging with Tc-99m MIBI in breast cancer seemed to be correlated with the levels of P-glycoprotein (Pgp) expression and angiogenesis in cancer tissues. For that reason, we evaluated whether significant relationship actually existed between the pattern of Tc-99m MIBI uptake in tumor tissue and tumoric factors including Pgp expression and angiogenesis. METHODS: Thirty-one untreated breast-cancer patients (later pathologically proved to have had invasive ductal carcinomas) were prospectively studied by using both Tc-99m MIBI scintigraphy on and immunohistochemical analyses of angiogenesis and Pgp expression in sugically removed tumor tissues. Both lateral and anterior planar images were obtained at 10 minutes and 3 hours after intravenous injection of 740 MBq Tc-99m MIBI. The tumor-to-normal breast ratio (T/N) and the washout index (WI, early T/N minus late T/N divided by early T/N) were calculated. RESULTS: A significant correlation was found between the T/N's at early and late images (r=0.54, p=0.002 on early images; r=0.47, p=0.006 on late images). The T/N's of early images were not different among the different groups of Pgp expression (p=0.3696) while those of late images were significantly different among the groups (p=0.0276). An even more significant difference was noted in the WI's among the groups (p=0.0015). A significant negative correlation was noted between the T/N of late images and Pgp expression (p=0.0276). An even stronger correlation was found between WI and Pgp expression (r=0.668, p=0.001). CONCLUSIONS: The tumoral uptake and washout of Tc-99m MIBI can be used as a simple functional test for angiogenesis and P-glycoprotein expression in untreated breast cancer.
Breast Neoplasms* ; Breast* ; Humans ; Injections, Intravenous ; P-Glycoprotein ; Population Characteristics* ; Prospective Studies ; Radionuclide Imaging*

PURPOSE: A retrospective study was performed o define the clninical significance of p53, P-glycoprotein (Pgp), and Glutathione S transferase-pi (GST-pi) immunohistochemical (IHC) expression in advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We reviewed fifty seven patients with advanced NSCLC who had undergone surgical resection or bronchoscopic biopsy between March 1997 and March 1999. IHC staining for p53, GST-pi, and Pgp was performed using formalin-fixed, paraffin-embedded specimens of the fifty seven patients. RESULTS: The IHC expression rate was 63% for p53, 28% for Pgp, and 53% for GST-pi, respectively. The median survival of the fifty seven patients was 45 weeks and the response rate was 38.6% (partial response, 22/57). The chemotherapy response and median survival of the p53 negative group (57% and 61 weeks) were better than those demonstrated by the p53 positive group (28% and 21 weeks) (p<0.05). Additionally, the GST-pi negative group showed a greater improvement of survival and response rate than the positive group (p<0.05). Pgp expression status appeared to have no significant differential effect on chemotherapy response and survival. CONCLUSION: These results suggest that immunohisto chemical staining of p53 and GST-pi may be useful in predicting the response to chemotherapy as well as survival in advanced NSCLC. However, this study is limited by its retrospective nature and the small numbers of tumors studied from a heterogenous group of patients.
Biopsy ; Carcinoma, Non-Small-Cell Lung* ; Drug Therapy ; Glutathione* ; Humans ; P-Glycoprotein* ; Retrospective Studies